The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•5 May 2026•

1 min read

Repligen Beats Q1 Estimates and Raises Full-Year 2026 Guidance

Key Facts

1Repligen reported Q1 revenue of $194.00 million, a 15% increase compared to the previous year.

2Earnings per share reached $0.48, surpassing analyst estimates of $0.38.

3The company increased its full-year 2026 adjusted EPS guidance to a range of $1.97 to $2.05.

Version History

1 additional source confirmed this story

Repligen reported robust financial results for the first quarter of 2026, with revenue reaching $194.00 million, a 15% increase year-over-year. Earnings per share (EPS) significantly outperformed expectations at $0.48, beating the consensus estimate of $0.38. Driven by this strong performance, the company has raised its full-year 2026 adjusted EPS guidance to a range of $1.97 to $2.05. This growth reflects a 23% increase in adjusted EPS, highlighting operational efficiency and positive momentum within the bioprocessing sector. The earnings beat has led analysts, including Matthew Stanton from Jefferies, to maintain a positive outlook on the stock. This upward revision in financial guidance is expected to bolster investor confidence in the company's long-term growth trajectory.